<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-145903" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Laboratory Evaluation of Tumor Biomarkers</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahadevarao Premnath</surname>
            <given-names>Sujatha</given-names>
          </name>
          <aff>Pondicherry Institute of Medical Science, Pondicherry University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zubair</surname>
            <given-names>Muhammad</given-names>
          </name>
          <aff>Indus Hospital &#x00026; Health Network</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sujatha Mahadevarao Premnath declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Zubair declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>10</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-145903.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Tumor biomarkers are substances synthesized by cancer cells or other body cells in response to cancer and released into the circulation.<xref ref-type="bibr" rid="article-145903.r1">[1]</xref> Tumor biomarkers vary widely in structure and may be simple molecules, such as catecholamines; well-characterized proteins, such as hormones, enzymes, or gene products; or more heterogeneous glycoproteins or mucins, such as carbohydrate antigen 125 (CA 125), which may be quantified by the antibodies used to measure them. Several important tumor biomarkers such as alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and human chorionic gonadotropin (hCG) are oncofetal antigens present in the normal fetus, expressed in minute concentrations by healthy tissues, but expressed at high concentrations by some malignancies.<xref ref-type="bibr" rid="article-145903.r2">[2]</xref></p>
        <p>Assays of tumor biomarkers are employed in various clinical settings and are an integral part of many cancer diagnoses and management plans. Using various techniques, these biomarkers may be assayed in selected body fluids such as blood, urine, and pleural&#x000a0;or peritoneal effusions. Assays of tumor biomarkers may aid in the screening and early diagnosis of malignancy, guide treatment decisions, monitor treatment response, assess disease progression, or detect cancer recurrence.<xref ref-type="bibr" rid="article-145903.r3">[3]</xref>&#x000a0;</p>
        <p>However, assays of tumor biomarkers have limitations and should not be used as standalone diagnostic tools.<xref ref-type="bibr" rid="article-145903.r4">[4]</xref>&#x000a0;The results of tumor biomarker assays are most&#x000a0;effective when interpreted with&#x000a0;clinical information, imaging studies, and pathological tissue examination to ensure a comprehensive assessment and facilitate an accurate diagnosis.</p>
        <p>The ideal tumor biomarker would be an inherently stable molecule with high specificity, sensitivity, accuracy, and reproducibility rates, offering cost-effective screening, diagnosis, and prognostic indication. However, no clinically employed tumor biomarker possesses all these characteristics.&#x000a0;Most tumor markers have limitations in specificity, sensitivity, or clinical utility, making it essential to use them in conjunction with other diagnostic tools for comprehensive patient evaluation and management.<xref ref-type="bibr" rid="article-145903.r1">[1]</xref><xref ref-type="bibr" rid="article-145903.r3">[3]</xref><xref ref-type="bibr" rid="article-145903.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-145903.s2" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>Cancer is not one disease but a group of diseases characterized by dysregulated cellular growth. Malignant neoplasms have the ability to infiltrate, invade, and destroy surrounding tissues.<xref ref-type="bibr" rid="article-145903.r6">[6]</xref>&#x000a0;Cancers are caused by genetic mutations that may be inherited or acquired through exposure to environmental carcinogens.<xref ref-type="bibr" rid="article-145903.r7">[7]</xref>&#x000a0;Carcinogens like tobacco smoke, asbestos, ionizing and ultraviolet radiation, and infections are associated with malignancy development.<xref ref-type="bibr" rid="article-145903.r8">[8]</xref>&#x000a0;</p>
        <p>Cancer is one of the leading causes of death worldwide, accounting for 10 million deaths yearly.<xref ref-type="bibr" rid="article-145903.r9">[9]</xref>&#x000a0;On average, 22.6% of women and 18.6% of men risk developing cancer before the age of 75 years.<xref ref-type="bibr" rid="article-145903.r10">[10]</xref>&#x000a0;In younger patients, the most commonly encountered malignancies are hematological. However, in older populations, breast, prostate, lung, and colorectal cancers are the most common; these four malignancies comprise more than&#x000a0;half of the cancer diagnoses made worldwide. Cancer incidence is increasing globally due to an aging population, lifestyle changes, and environmental pollution.</p>
        <p>Bence Jones protein was the first tumor biomarker described in the literature.<xref ref-type="bibr" rid="article-145903.r11">[11]</xref>&#x000a0;Since then, many protein- and hormone-based tumor biomarkers have been described and introduced into clinical practice. More recently, proteomics and genomics technology&#x000a0;have permitted the assay of various&#x000a0;genetic and molecular tumor biomarkers using microarray techniques.</p>
      </sec>
      <sec id="article-145903.s3" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>The National Academy of Clinical Biochemistry (NCAB) has established preanalytical quality guidelines for tumor biomarkers.<xref ref-type="bibr" rid="article-145903.r12">[12]</xref>&#x000a0;Assays of serum should be collected in red-top containers. Other body fluids to be assayed should be collected in fluid-specific containers.<xref ref-type="bibr" rid="article-145903.r13">[13]</xref>&#x000a0;Chromosomal assessment of bone marrow requires 2 to 3 mL of bone marrow from the first pull of the repositioned needle during marrow extraction.<xref ref-type="bibr" rid="article-145903.r14">[14]</xref>&#x000a0;Whole blood is required for microarray techniques.<xref ref-type="bibr" rid="article-145903.r15">[15]</xref>&#x000a0;Immunohistochemistry&#x000a0;staining requires approximately a 1-mL tissue volume; the sample should be deparaffinized and rehydrated before staining.<xref ref-type="bibr" rid="article-145903.r16">[16]</xref></p>
        <p>It is preferable to assay all samples immediately. Tissue or bone marrow samples for chromosomal assessment, fluorescent in situ hybridization, or microarray should not be frozen. Salivary contamination may cause falsely increased concentrations of CEA and&#x000a0;carbohydrate antigen 19-9.<xref ref-type="bibr" rid="article-145903.r17">[17]</xref>&#x000a0;Specimens can be collected at any time of the day; no diurnal variation has been documented. Specimens should always be collected before any invasive procedures since tissue trauma may cause a transient release of tumor markers into the circulation. For example, prostate-specific antigen (PSA) levels increase following urinary catheterization and prostate biopsy, and CEA levels increase after colonoscopy. Tumor biomarker assays should be ideally repeated after 2 to 3 weeks for additional evidence.<xref ref-type="bibr" rid="article-145903.r18">[18]</xref></p>
        <p>The commonly measured tumor markers are generally stable. However, serum or plasma should be separated from the clot and stored at 4 &#x000b0;C in the short term or below -30 &#x000b0;C as soon as possible; relevant guidelines should be followed if available. For prolonged storage, specimens should be stored at -70 &#x000b0;C.<xref ref-type="bibr" rid="article-145903.r19">[19]</xref>&#x000a0;Heat treatments should be avoided, such as those used to deplete serum complement components or inactivate the human immunodeficiency virus.&#x000a0;Avoidance of heat treatments is&#x000a0;particularly true for PSA and hCG, which may dissociate into its free &#x003b1;- and &#x003b2;-subunits at increased temperatures.<xref ref-type="bibr" rid="article-145903.r20">[20]</xref></p>
      </sec>
      <sec id="article-145903.s4" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>Many malignancies have one or more tumor biomarkers that are routinely measured in the course of diagnosing, managing, and monitoring for recurrence of the neoplasm. Some of these malignancies and their respective biomarkers&#x000a0;are listed in&#x000a0;<bold>Table 1.</bold> Malignancies and Related Tumor Biomarkers.</p>
        <table-wrap id="article-145903.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Malignancies and Related Tumor Biomarkers.</title>
          </caption>
          <table border="1" cellspacing="1" cellpadding="10">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<bold>&#x000a0;Malignancy&#x000a0;</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>&#x000a0;Related tumor markers&#x000a0;</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>&#x000a0;Bronchogenic:&#x000a0;</p>
<p>&#x000a0;Small cell carcinoma&#x000a0;</p>
<p>&#x000a0;Adenocarcinoma&#x000a0;</p>
<p>&#x000a0;Squamous cell carcinoma</p>
</td>
                <td rowspan="1" colspan="1">
<p>&#x000a0;Neuron-specific enolase (NSE), Pro-gastrin&#x02013;releasing peptide (pro-GRP)&#x000a0;</p>
<p>&#x000a0;Carcinoembryonic antigen (CEA)</p>
<p>&#x000a0;Squamous cell carcinoma antigen (SCC), Cytokeratin 19 fragment</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>&#x000a0;Ovarian:</p>
<p>&#x000a0;Epithelial&#x000a0;</p>
<p>&#x000a0;Mucinous&#x000a0;</p>
<p>&#x000a0;Nonepithelial&#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
<p>&#x000a0;Carbohydrate antigen 125 (CA 125)</p>
<p>&#x000a0;CEA</p>
<p>&#x000a0;Inhibin A and B&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;Colorectal Adenocarcinoma</td>
                <td rowspan="1" colspan="1">
<p>&#x000a0;CEA</p>
<p>&#x000a0;Carbohydrate antigen 19-9 (CA 19-9)</p>
<p>&#x000a0;Tissue plasminogen activator (TPA)</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;Hepatocellular Carcinoma</td>
                <td rowspan="1" colspan="1">&#x000a0;Alpha-fetoprotein (AFP)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;Pancreatic Adenocarcinoma</td>
                <td rowspan="1" colspan="1">
<p>&#x000a0;CA 19-9</p>
<p>&#x000a0;CEA</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;Prostate Adenocarcinoma</td>
                <td rowspan="1" colspan="1">
<p>&#x000a0;Prostate-specific antigen (PSA)</p>
<p>&#x000a0;Prostatic acid phosphatase (PAP)</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;Germ cell tumors&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p>&#x000a0;Human chorionic gonadotropin (HCG)</p>
<p>&#x000a0;AFP</p>
<p>&#x000a0;Lactate dehydrogenase</p>
<p>&#x000a0;Placental alkaline phosphatase&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;Breast&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p>&#x000a0;Carbohydrate&#x000a0;antigen 15-3 (CA 15-3)</p>
<p>&#x000a0;Carbohydrate antigen 27.29 (CA 27.29)</p>
<p>&#x000a0;Estrogen and progesterone receptors (ER, PR)</p>
<p>&#x000a0;Human epidermal growth factor receptor 2 (Her2)</p>
<p>&#x000a0;Urokinase plasminogen activator</p>
<p>&#x000a0;Plasminogen activator inhibitor</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-145903.s5" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>Various assays can be employed when assessing tumor biomarkers. The most commonly utilized testing procedures include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Enzyme assays:</bold> Most enzymatic tumor biomarkers, except PSA, are quantified using an enzyme activity assay; enzymatic activity is used to determine the&#x000a0;amount of biomarkers in the tested sample.<xref ref-type="bibr" rid="article-145903.r1">[1]</xref>&#x000a0;Enzyme activity assays are performed by adding excess substrate and cofactors to the prepared sample, noting their conversion rate to the product. Alternatively, kinetic enzyme assays may be used, which measure substrate at specific, predetermined intervals.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Immunoassays:</bold>&#x000a0;Immunoassays are based on the principles of the antigen-antibody reaction; when measuring tumor biomarkers, the biomarker serves as the "antigen," and antigen-specific antibodies are used. Commonly&#x000a0;employed immunoassay methods are enzyme-linked immunosorbent assay (ELISA), electrochemiluminescence immunoassay, and immunohistochemistry. Many tumor biomarkers are quantified using immunoassay techniques, including AFP, CEA, hCG, prolactin, calcitonin, and carbohydrate antigens.<xref ref-type="bibr" rid="article-145903.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p><bold>High-performance liquid chromatography (HPLC):</bold>&#x000a0;HPLC is primarily employed when identifying catecholamines and their metabolites in plasma and urine. HPLC runs analytes over a column and separates them based on their physical properties.<xref ref-type="bibr" rid="article-145903.r22">[22]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Immunohistochemistry:</bold>&#x000a0;Immunohistochemistry is a type of immunoassay employed when tumor biomarkers must be detected in solid tissue samples obtained via biopsy. A thin tissue slice is placed on a glass slide, antibodies are added against the specific antigen, and colorimetric secondary antibodies are used to detect antigen-antibody binding. Immunohistochemistry is utilized in the detection of estrogen and progesterone receptors and Her2.<xref ref-type="bibr" rid="article-145903.r23">[23]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Fluorescent in situ hybridization (FISH):</bold>&#x000a0;FISH identifies specific genetic mutations in tumor cells.<xref ref-type="bibr" rid="article-145903.r24">[24]</xref>&#x000a0;This technique uses fluorescent-labeled&#x000a0;DNA probes, which hybridize to specific target sequences in cells, allowing their visualization under a fluorescence microscope. <italic toggle="yes">APC </italic>(adenomatous polyposis coli) and&#x000a0;<italic toggle="yes">ras</italic>&#x000a0;mutations and Her2 overexpression are identified using FISH.<xref ref-type="bibr" rid="article-145903.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Polymerase chain reaction (PCR):</bold>&#x000a0;PCR is a technique that amplifies a specific DNA segment by cycling through denaturation, annealing of primers, and extension using a thermostable DNA polymerase. PCR is used to detect the&#x000a0;<italic toggle="yes">bcr-abl1</italic>&#x000a0;fusion present in many forms of chronic myeloid leukemia.&#x000a0;PCR is also used to detect microsatellite instability or mutations in genes like K-<italic toggle="yes">ras</italic>, N-<italic toggle="yes">ras</italic>, and <italic toggle="yes">BRAF</italic>, which have prognostic and predictive implications in colorectal cancer.<xref ref-type="bibr" rid="article-145903.r26">[26]</xref>&#x000a0;PCR is utilized to detect HER2 gene amplification, which helps identify patients who may benefit from HER2-targeted therapy.</p>
          </list-item>
          <list-item>
            <p><bold>Microarrays:</bold>&#x000a0;Microarrays permit the identification and evaluation of multiple genetic mutations or overexpression simultaneously using a solid two-dimensional support material such as a silicon chip with multiple spots containing sequences from thousands of genes. Fluorescent-labeled complementary DNA from the specimen can hybridize, and the signal is measured. Microarrays have many applications; in oncology, they are used for genetic profiling in ovarian and colorectal cancer, genetically typing leukemias, and identifying the tumor of origin in metastatic lesions.<xref ref-type="bibr" rid="article-145903.r27">[27]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145903.s6" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p><bold>Disadvantages of Tumor Biomarkers</bold>&#x000a0;</p>
        <p>Variations in sample collection, handling, storage, and assay techniques can alter the biomarker profile in a given sample. Standardization of the preanalytical and analytical variables&#x000a0;may&#x000a0;mitigate these variations. Very low concentrations of tumor biomarkers&#x000a0;are frequently encountered in early-stage tumors;&#x000a0;a highly sensitive assay is required.<xref ref-type="bibr" rid="article-145903.r28">[28]</xref>&#x000a0;Tumor biomarkers also have inherent drawbacks and disadvantages, including:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Lack of specificity:</bold> Some tumor biomarkers are produced by normal and cancerous cells and are elevated in many noncancerous conditions. This lack of specificity can lead to false-positive results, potentially leading to unnecessary diagnostic procedures or treatment interventions.<xref ref-type="bibr" rid="article-145903.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Lack of sensitivity:</bold> Tumor biomarkers may not be elevated in all individuals with a specific cancer, particularly in the early stages of the disease. This lack of sensitivity can result in false-negative results, where biomarker levels are within normal ranges despite the presence of cancer. Such a scenario may&#x000a0;delay the diagnosis and lead to missed opportunities for early intervention and treatment.<xref ref-type="bibr" rid="article-145903.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Biological variability:</bold> Individual patients can exhibit biological variability in tumor biomarker levels, making it challenging to establish universal reference ranges or cut-off values for diagnosis or monitoring.<xref ref-type="bibr" rid="article-145903.r30">[30]</xref>&#x000a0;Biological factors such as age, gender, genetics, and comorbidities can influence biomarker levels, leading to variations in results among individuals.</p>
          </list-item>
          <list-item>
            <p><bold>Analytical variability:</bold> Variations in assay platforms, reagents, and laboratory techniques can contribute to analytical variability in tumor marker measurements. Inconsistent methods and lack of standardization can impact the accuracy and reliability of results, hindering data comparison across different laboratories or over time.<xref ref-type="bibr" rid="article-145903.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Limited diagnostic utility:</bold> Tumor biomarker assays are unsuitable as standalone diagnostic tools for cancer&#x000a0;and should be used in conjunction with other diagnostic methods, such as imaging studies, biopsies, or clinical evaluations, to establish a comprehensive diagnosis.<xref ref-type="bibr" rid="article-145903.r2">[2]</xref> Relying solely on tumor biomarker assays may lead to incomplete or inaccurate diagnostic conclusions.</p>
          </list-item>
        </list>
        <p>
<bold>Commonly Encountered Interferences</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>High-dose hook effect:</bold>&#x000a0;This effect is characterized by falsely low values at high tumor biomarker concentration&#x000a0;and is commonly seen in patients for whom the assay is being performed for the first time.<xref ref-type="bibr" rid="article-145903.r32">[32]</xref>&#x000a0;The high-dose hook effect can be avoided by using solid-phase antibodies of higher binding capacity, performing the assay in two sample dilutions, and implementing proper wash steps.</p>
          </list-item>
          <list-item>
            <p><bold>Specimen carryover:</bold> This interference is most commonly encountered when dealing with high-concentration markers in the assay.</p>
          </list-item>
          <list-item>
            <p><bold>Interferences from heterophilic or human antimouse antibodies:</bold> Samples from patients who have undergone monoclonal antibody therapy or have circulating anti-animal antibodies&#x000a0;may return&#x000a0;falsely high or low values.<xref ref-type="bibr" rid="article-145903.r33">[33]</xref>&#x000a0;Identifying the presence of interfering antibodies requires a high degree of clinical suspicion that a tumor marker result is incorrect; this clinical suspicion may be strengthened if pertinent clinical information is available. Once suspected, potential interference can be investigated by testing the specimen at various dilutions, retesting after treatment with a commercially available blocking agent, adding additional nonimmune mouse serum to the reaction mixture and reassaying, or by reassaying the specimen using a different method provided by another manufacturer, preferably using a different methodology.<xref ref-type="bibr" rid="article-145903.r34">[34]</xref> Caution should be applied&#x000a0;when interpreting these results.</p>
          </list-item>
          <list-item>
            <p><bold>Pharmaceutical interference: </bold>Anticoagulants such as ethylenediaminetetraacetic acid (EDTA) might interfere with some assays.<xref ref-type="bibr" rid="article-145903.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145903.s7" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>The reported results should include reference intervals specific to the employed method and derived from an appropriate healthy population.<xref ref-type="bibr" rid="article-145903.r36">[36]</xref> If possible, the technique used for the assay should be mentioned when reporting results.&#x000a0;If there has been a method or technique change, the laboratory should indicate whether it will likely influence the interpretation of the trend in results. There should be a defined protocol if methods are changed, and the likely effect should be communicated to clinical users before the change.<xref ref-type="bibr" rid="article-145903.r3">[3]</xref> Managing the change may necessitate analyzing the previous specimen by the new method or requesting another specimen to reestablish the baseline or confirm the trend in biomarker concentrations.<xref ref-type="bibr" rid="article-145903.r37">[37]</xref></p>
        <p>Instead of interpreting a single value, observing the overall trend of the biomarker concentration resulting from interval testing over time is more likely to provide valuable insight into the status of the disease. Graphical reporting can offer a clear and concise way to interpret the trend in biomarker concentrations over time.<xref ref-type="bibr" rid="article-145903.r1">[1]</xref>&#x000a0;Recording brief clinical information alongside the laboratory data enhances result interpretation. Recommendations on the need for confirmatory specimens and the next assay interval can also be included.</p>
        <p>Reporting critical increases in tumor biomarker concentrations&#x000a0;and accounting for&#x000a0;the analytical performance of the test, biological variations, and individual reference intervals&#x000a0;contributes&#x000a0;to an earlier diagnosis of relapse.&#x000a0;The percentage increase or decrease that constitutes a significant change should be defined, account for analytical and biological variation, delineate the expected rate of change in benign and malignant conditions and report the time between samples.<xref ref-type="bibr" rid="article-145903.r38">[38]</xref> For tumor biomarkers, differences in the magnitudes of their biological variation contribute significantly to these percentages.<xref ref-type="bibr" rid="article-145903.r39">[39]</xref></p>
        <p>The half-life of the tumor biomarker must be considered when interpreting test results. Before surgical intervention, use the known half-life of the biomarker to estimate the time required for the level to decline to a normal or undetectable level.<xref ref-type="bibr" rid="article-145903.r40">[40]</xref>&#x000a0;If the quantitative decline of a tumor biomarker will be used to determine the likelihood of complete tumor resection, biomarkers should not be measured until at least 2 weeks and ideally 4 weeks postoperatively.<xref ref-type="bibr" rid="article-145903.r1">[1]</xref>&#x000a0;The rate of decline may be affected by underlying comorbidities such as renal or hepatic dysfunction.<xref ref-type="bibr" rid="article-145903.r41">[41]</xref> For example, serum CEA often remains inappropriately elevated in patients with underlying hepatic dysfunction due to inefficient hepatic metabolism of the serum biomarker.<xref ref-type="bibr" rid="article-145903.r42">[42]</xref>&#x000a0;Persistently elevated serum&#x000a0;&#x003b2;-<italic toggle="yes">2&#x000a0;</italic>microglobulin&#x000a0;is frequently noted in patients with acute and chronic renal disease; even the small-sized &#x003b2;-<italic toggle="yes">2&#x000a0;</italic>microglobulin molecule has difficulty passing through the injured glomerular apparatus.<xref ref-type="bibr" rid="article-145903.r43">[43]</xref></p>
        <p>If appropriate to the specific neoplasm, clinicians should consider ordering a panel of tumor biomarkers to increase the diagnostic sensitivity and specificity of the test.<xref ref-type="bibr" rid="article-145903.r1">[1]</xref>&#x000a0;Many malignancies have a heterogeneous cellular composition and express more than one tumor biomarker; measurement of multiple biomarkers is frequently required to achieve a &#x0003e;90% detection sensitivity.<xref ref-type="bibr" rid="article-145903.r13">[13]</xref></p>
      </sec>
      <sec id="article-145903.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Tumor biomarkers each possess some degree of clinical utility and correlate to one or several specific malignancies. Many tumor biomarkers are expressed to some degree by normal, healthy cells or tissues, and levels of circulating biomarkers can be affected by benign conditions. The sensitivity and specificity of each assay must be considered within the context of the clinical condition of the patient.<xref ref-type="bibr" rid="article-145903.r30">[30]</xref>&#x000a0;</p>
        <p>There are many national and international guidelines on the selection and utilization of tumor biomarkers. The National Academy of Clinical Biochemistry, the European Group on Tumor Markers, the American Cancer Society, the National Comprehensive Cancer Network, and the National Institute for Health and Care Excellence have established recommendations regarding the use of tumor biomarkers based on the level of available evidence.&#x000a0;</p>
        <p>The clinical significance of some commonly measured tumor biomarkers is described in&#x000a0;<bold>Table 2.</bold> The Clinical Significance of Selected Tumor Biomarkers.</p>
        <table-wrap id="article-145903.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. The Clinical Significance of Selected Tumor Biomarkers.</title>
          </caption>
          <table style="width: 800px; height: 2628px; margin-left: auto; margin-right: auto;" border="1" cellspacing="1" cellpadding="10">
            <tbody>
              <tr style="height: 26.6px;">
                <td style="width: 267px; height: 26.6px; text-align: center;" rowspan="1" colspan="1">
<bold>Tumor biomarker&#x000a0;</bold>
</td>
                <td style="width: 107.2px; height: 26.6px; text-align: center;" rowspan="1" colspan="1">
<bold>Family&#x000a0;</bold>
</td>
                <td style="width: 191.8px; height: 26.6px; text-align: center;" rowspan="1" colspan="1">
<bold>Chemistry&#x000a0;</bold>
</td>
                <td style="width: 198px; height: 26.6px; text-align: center;" rowspan="1" colspan="1">
<bold>Clinical Significance&#x000a0;</bold>
</td>
                <td style="width: 192px; height: 26.6px; text-align: center;" rowspan="1" colspan="1">
<bold>Limitation</bold>
</td>
              </tr>
              <tr style="height: 65px;">
                <td style="width: 267px; height: 65px; text-align: center;" rowspan="1" colspan="1">Alpha-fetoprotein (AFP)</td>
                <td style="width: 107.2px; height: 65px; text-align: center;" rowspan="1" colspan="1">Oncofetal antigen</td>
                <td style="width: 191.8px; height: 65px; text-align: center;" rowspan="1" colspan="1">Glycoprotein synthesized from the yolk sac and embryonic liver.&#x000a0;</td>
                <td style="width: 198px; height: 65px; text-align: center;" rowspan="1" colspan="1">Diagnosis and monitoring of hepatocellular carcinoma, hepatoblastoma, and germ cell tumors. Prognostic marker of germ cell tumor.<xref ref-type="bibr" rid="article-145903.r3">[3]</xref></td>
                <td style="width: 192px; height: 65px; text-align: center;" rowspan="1" colspan="1">Elevated in pregnancy, neonates, benign liver diseases, and diseases of the gastrointestinal tract.<xref ref-type="bibr" rid="article-145903.r44">[44]</xref></td>
              </tr>
              <tr style="height: 98px;">
                <td style="width: 267px; height: 98px; text-align: center;" rowspan="1" colspan="1">Carcinoembryonic antigen (CEA)</td>
                <td style="width: 107.2px; height: 98px; text-align: center;" rowspan="1" colspan="1">Oncofetal antigen</td>
                <td style="width: 191.8px; height: 98px; text-align: center;" rowspan="1" colspan="1">Glycoprotein isolated from fetal gastrointestinal tissue.&#x000a0;</td>
                <td style="width: 198px; height: 98px; text-align: center;" rowspan="1" colspan="1">Monitoring response to therapy and relapse of colorectal adenocarcinomas.<xref ref-type="bibr" rid="article-145903.r45">[45]</xref></td>
                <td style="width: 192px; height: 98px; text-align: center;" rowspan="1" colspan="1">Serum levels in early-stage and poorly differentiated cancer are low and elevated in benign renal, liver, and lung diseases. Not specific to colorectal malignancy.<xref ref-type="bibr" rid="article-145903.r45">[45]</xref>&#x000a0;</td>
              </tr>
              <tr style="height: 85px;">
                <td style="width: 267px; height: 85px; text-align: center;" rowspan="1" colspan="1">Alkaline phosphatase (ALP)</td>
                <td style="width: 107.2px; height: 85px; text-align: center;" rowspan="1" colspan="1">Enzyme</td>
                <td style="width: 191.8px; height: 85px; text-align: center;" rowspan="1" colspan="1">Enzymes of bone, placenta, small bowel, and biliary tract. Isoenzymes are more specific.</td>
                <td style="width: 198px; height: 85px; text-align: center;" rowspan="1" colspan="1">Elevated in osteosarcoma,&#x000a0;cholangiocarcinoma, and bony metastases.<xref ref-type="bibr" rid="article-145903.r46">[46]</xref></td>
                <td style="width: 192px; height: 85px; text-align: center;" rowspan="1" colspan="1">Serum levels are elevated in normal pregnancy and benign diseases of bone, small bowel, and the heaptobiliary system.<xref ref-type="bibr" rid="article-145903.r47">[47]</xref></td>
              </tr>
              <tr style="height: 117px;">
                <td style="width: 267px; height: 117px; text-align: center;" rowspan="1" colspan="1">Lactate dehydrogenase (LDH)&#x000a0;</td>
                <td style="width: 107.2px; height: 117px; text-align: center;" rowspan="1" colspan="1">Enzyme</td>
                <td style="width: 191.8px; height: 117px; text-align: center;" rowspan="1" colspan="1">Enzyme found in almost all body cells that interconverts pyruvate and lactate.&#x000a0;</td>
                <td style="width: 198px; height: 117px; text-align: center;" rowspan="1" colspan="1">Elevated in almost all malignancies due to its ubiquitous nature.&#x000a0;<xref ref-type="bibr" rid="article-145903.r48">[48]</xref></td>
                <td style="width: 192px; height: 117px; text-align: center;" rowspan="1" colspan="1">Elevated in many anemias and any disease characterized by cellular destruction.</td>
              </tr>
              <tr style="height: 85px;">
                <td style="width: 267px; height: 85px; text-align: center;" rowspan="1" colspan="1">
<p>Prostatic acid phosphatase (PAP)&#x000a0;</p>
</td>
                <td style="width: 107.2px; height: 85px; text-align: center;" rowspan="1" colspan="1">
<p>Enzyme</p>
</td>
                <td style="width: 191.8px; height: 85px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Glycoprotein dimer&#x000a0;</td>
                <td style="width: 198px; height: 85px; text-align: center;" rowspan="1" colspan="1">Monitoring response to therapy and relapse of prostatic adenocarcinoma.&#x000a0;<xref ref-type="bibr" rid="article-145903.r49">[49]</xref></td>
                <td style="width: 192px; height: 85px; text-align: center;" rowspan="1" colspan="1">High serum levels encountered in some lysosomal storage disorders and many benign prostatic diseases.</td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 267px; height: 39px; text-align: center;" rowspan="1" colspan="1">Neuron specific enolase (NSE)</td>
                <td style="width: 107.2px; height: 39px; text-align: center;" rowspan="1" colspan="1">Enzyme</td>
                <td style="width: 191.8px; height: 39px; text-align: center;" rowspan="1" colspan="1">Dimer of the enzyme enolase, synthesized by neuroendocrine cells.</td>
                <td style="width: 198px; height: 39px; text-align: center;" rowspan="1" colspan="1">Elevated in neuroblastoma, small cell lung cancer, and pancreatic adenocarcinoma.&#x000a0;</td>
                <td style="width: 192px; height: 39px; text-align: center;" rowspan="1" colspan="1">Delays in the assay should be avoided.<xref ref-type="bibr" rid="article-145903.r50">[50]</xref></td>
              </tr>
              <tr style="height: 52px;">
                <td style="width: 267px; height: 52px; text-align: center;" rowspan="1" colspan="1">Human chorionic gonadotropin (hCG)</td>
                <td style="width: 107.2px; height: 52px; text-align: center;" rowspan="1" colspan="1">Hormone</td>
                <td style="width: 191.8px; height: 52px; text-align: center;" rowspan="1" colspan="1">Glycoprotein hormone synthesized by placental syncytiotrophoblasts.</td>
                <td style="width: 198px; height: 52px; text-align: center;" rowspan="1" colspan="1">Diagnosis, prognosis, and monitoring treatment response of gestational trophoblastic tumor and germ cell tumors.<xref ref-type="bibr" rid="article-145903.r3">[3]</xref></td>
                <td style="width: 192px; height: 52px; text-align: center;" rowspan="1" colspan="1">Elevated in normal pregnancy.<xref ref-type="bibr" rid="article-145903.r51">[51]</xref></td>
              </tr>
              <tr style="height: 65px;">
                <td style="width: 267px; height: 65px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Prolactin&#x000a0;</td>
                <td style="width: 107.2px; height: 65px; text-align: center;" rowspan="1" colspan="1">Hormone</td>
                <td style="width: 191.8px; height: 65px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Anterior pituitary hormone&#x000a0;</td>
                <td style="width: 198px; height: 65px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Pituitary adenocarcinoma</td>
                <td style="width: 192px; height: 65px; text-align: center;" rowspan="1" colspan="1">Diurnal variation is seen. Seruum levels may be elevated due to benign pituitary prolactinomas and in response to many medications.<xref ref-type="bibr" rid="article-145903.r52">[52]</xref></td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 267px; height: 39px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Calcitonin&#x000a0;</td>
                <td style="width: 107.2px; height: 39px; text-align: center;" rowspan="1" colspan="1">Hormone</td>
                <td style="width: 191.8px; height: 39px; text-align: center;" rowspan="1" colspan="1">Mucin glycoprotein secreted by thyroid parafollicular C cells.</td>
                <td style="width: 198px; height: 39px; text-align: center;" rowspan="1" colspan="1">Diagnosis and monitoring of medullary thyroid carcinoma.</td>
                <td style="width: 192px; height: 39px; text-align: center;" rowspan="1" colspan="1">Falsely elevated in Zollinger-Ellison syndrome, pernicious anemia, and chronic renal disease.<xref ref-type="bibr" rid="article-145903.r53">[53]</xref></td>
              </tr>
              <tr style="height: 91px;">
                <td style="width: 267px; height: 91px; text-align: center;" rowspan="1" colspan="1">Catecholamines and metanephrines&#x000a0;</td>
                <td style="width: 107.2px; height: 91px; text-align: center;" rowspan="1" colspan="1">Hormone</td>
                <td style="width: 191.8px; height: 91px; text-align: center;" rowspan="1" colspan="1">Biogenic amines produced by the adrenal gland and sympathetic nervous system.</td>
                <td style="width: 198px; height: 91px; text-align: center;" rowspan="1" colspan="1">Diagnosis and monitoring of neuroblastoma, pheochromocytoma, and paragangliomas.<xref ref-type="bibr" rid="article-145903.r54">[54]</xref>&#x000a0;&#x000a0;</td>
                <td style="width: 192px; height: 91px; text-align: center;" rowspan="1" colspan="1">Serum levels may be elevated in response to many medications and normal diurnal variation is seen.</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 267px; height: 26px; text-align: center;" rowspan="1" colspan="1">Serotonin</td>
                <td style="width: 107.2px; height: 26px; text-align: center;" rowspan="1" colspan="1">Hormone</td>
                <td style="width: 191.8px; height: 26px; text-align: center;" rowspan="1" colspan="1">Biogenic amine</td>
                <td style="width: 198px; height: 26px; text-align: center;" rowspan="1" colspan="1">Diagnosis and monitoring of carcinoid tumors.<xref ref-type="bibr" rid="article-145903.r55">[55]</xref>&#x000a0;</td>
                <td style="width: 192px; height: 26px; text-align: center;" rowspan="1" colspan="1">Levels may be elevated after consuming meat and fruits.</td>
              </tr>
              <tr style="height: 78px;">
                <td style="width: 267px; height: 78px; text-align: center;" rowspan="1" colspan="1">Prostate-specific antigen (PSA)</td>
                <td style="width: 107.2px; height: 78px; text-align: center;" rowspan="1" colspan="1">Protein</td>
                <td style="width: 191.8px; height: 78px; text-align: center;" rowspan="1" colspan="1">Glycoprotein with serine protease activity&#x000a0;that circulates free or bound to antichymotrypsin or macroglobulin.&#x000a0;</td>
                <td style="width: 198px; height: 78px; text-align: center;" rowspan="1" colspan="1">Screening, risk assessment, and monitoring for prostatic cancer.<xref ref-type="bibr" rid="article-145903.r56">[56]</xref></td>
                <td style="width: 192px; height: 78px; text-align: center;" rowspan="1" colspan="1">Serum levels may be elevated in many benign prostatic diseases and after manipulation of the male lower genitourinary tract.<xref ref-type="bibr" rid="article-145903.r57">[57]</xref></td>
              </tr>
              <tr style="height: 52px;">
                <td style="width: 267px; height: 52px; text-align: center;" rowspan="1" colspan="1">Carbohydrate antigen 15-3 (CA 15-3)</td>
                <td style="width: 107.2px; height: 52px; text-align: center;" rowspan="1" colspan="1">Protein</td>
                <td style="width: 191.8px; height: 52px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Mucin glycoprotein</td>
                <td style="width: 198px; height: 52px; text-align: center;" rowspan="1" colspan="1">Used in conjunction with CEA for monitoring breast cancer. Used as a marker for treatment response.</td>
                <td style="width: 192px; height: 52px; text-align: center;" rowspan="1" colspan="1">Elevated in benign and malignant breast, ovarian, and liver disease.<xref ref-type="bibr" rid="article-145903.r50">[50]</xref></td>
              </tr>
              <tr style="height: 104px;">
                <td style="width: 267px; height: 104px; text-align: center;" rowspan="1" colspan="1">Carbohydrate antigen 19-9 (CA 19-9)</td>
                <td style="width: 107.2px; height: 104px; text-align: center;" rowspan="1" colspan="1">Protein</td>
                <td style="width: 191.8px; height: 104px; text-align: center;" rowspan="1" colspan="1">Lewis blood grouping glycolipid</td>
                <td style="width: 198px; height: 104px; text-align: center;" rowspan="1" colspan="1">Increased in pancreatic and hepatobiliary cancer. Monitoring pancreatic cancer following resection.</td>
                <td style="width: 192px; height: 104px; text-align: center;" rowspan="1" colspan="1">Specimens contaminated with saliva may show high CA 19-9 values. Low or absent levels in patients who are negative for the Lewis blood group.<xref ref-type="bibr" rid="article-145903.r17">[17]</xref></td>
              </tr>
              <tr style="height: 52px;">
                <td style="width: 267px; height: 52px; text-align: center;" rowspan="1" colspan="1">Carbohydrate antigen 125 (CA 125)</td>
                <td style="width: 107.2px; height: 52px; text-align: center;" rowspan="1" colspan="1">Protein</td>
                <td style="width: 191.8px; height: 52px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Mucin glycoprotein&#x000a0;</td>
                <td style="width: 198px; height: 52px; text-align: center;" rowspan="1" colspan="1">Screening and monitoring ovarian epithelial carcinoma.</td>
                <td style="width: 192px; height: 52px; text-align: center;" rowspan="1" colspan="1">CA 125 is also made by the pleurae, pericardium, and peritoneum and will be elevated in benign diseases affecting those tissues.<xref ref-type="bibr" rid="article-145903.r58">[58]</xref></td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 267px; height: 39px; text-align: center;" rowspan="1" colspan="1">&#x003b2;-<italic toggle="yes">2 </italic>microglobulin&#x000a0;</td>
                <td style="width: 107.2px; height: 39px; text-align: center;" rowspan="1" colspan="1">Protein</td>
                <td style="width: 191.8px; height: 39px; text-align: center;" rowspan="1" colspan="1">Component of major histocompatibility complex Class I (MHC Class I)</td>
                <td style="width: 198px; height: 39px; text-align: center;" rowspan="1" colspan="1">Increased in chronic lymphocytic leukemia, multiple myeloma, and B-cell neoplasms.<xref ref-type="bibr" rid="article-145903.r3">[3]</xref></td>
                <td style="width: 192px; height: 39px; text-align: center;" rowspan="1" colspan="1">May be elevated in acute and chronic renal disease and active HIV infection.</td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 267px; height: 39px; text-align: center;" rowspan="1" colspan="1">Thyroglobulin&#x000a0;</td>
                <td style="width: 107.2px; height: 39px; text-align: center;" rowspan="1" colspan="1">Protein</td>
                <td style="width: 191.8px; height: 39px; text-align: center;" rowspan="1" colspan="1">Glycoprotein dimer&#x000a0;</td>
                <td style="width: 198px; height: 39px; text-align: center;" rowspan="1" colspan="1">Monitoring differentiated thyroid carcinoma.<xref ref-type="bibr" rid="article-145903.r59">[59]</xref>&#x000a0;</td>
                <td style="width: 192px; height: 39px; text-align: center;" rowspan="1" colspan="1">Autoantibodies of many thyroid diseases falsely elevated serum thyroglobulin.&#x000a0;</td>
              </tr>
              <tr style="height: 65px;">
                <td style="width: 267px; height: 65px; text-align: center;" rowspan="1" colspan="1">Human epidermal growth factor receptor 2 (Her2)</td>
                <td style="width: 107.2px; height: 65px; text-align: center;" rowspan="1" colspan="1">Protein</td>
                <td style="width: 191.8px; height: 65px; text-align: center;" rowspan="1" colspan="1">Glycoprotein of tyrosine kinase receptor family activation which causes cell growth and proliferation.</td>
                <td style="width: 198px; height: 65px; text-align: center;" rowspan="1" colspan="1">HER2 overexpression may be seen in breast,&#x000a0;ovarian, and endometrial carcinoma.<xref ref-type="bibr" rid="article-145903.r60">[60]</xref></td>
                <td style="width: 192px; height: 65px; text-align: center;" rowspan="1" colspan="1">Varying expressions in different areas of the tumor.</td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 267px; height: 39px; text-align: center;" rowspan="1" colspan="1">Estrogen and progesterone receptors (ER, PR)</td>
                <td style="width: 107.2px; height: 39px; text-align: center;" rowspan="1" colspan="1">Protein</td>
                <td style="width: 191.8px; height: 39px; text-align: center;" rowspan="1" colspan="1">Nuclear transcription factor and&#x000a0; steroid receptor&#x000a0;</td>
                <td style="width: 198px; height: 39px; text-align: center;" rowspan="1" colspan="1">Predicting responsiveness&#x000a0;of breast cancer to antihormonal therapies.<xref ref-type="bibr" rid="article-145903.r60">[60]</xref></td>
                <td style="width: 192px; height: 39px; text-align: center;" rowspan="1" colspan="1">
<p>Biomarker expression changes over time.</p>
</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 267px; height: 26px; text-align: center;" rowspan="1" colspan="1">&#x000a0;<italic toggle="yes">TP53</italic></td>
                <td style="width: 107.2px; height: 26px; text-align: center;" rowspan="1" colspan="1">Genetic marker</td>
                <td style="width: 191.8px; height: 26px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Tumor suppressor gene</td>
                <td style="width: 198px; height: 26px; text-align: center;" rowspan="1" colspan="1">Most commonly mutated gene in human cancer.<xref ref-type="bibr" rid="article-145903.r3">[3]</xref>&#x000a0;</td>
                <td style="width: 192px; height: 26px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Will be elevated in the presence&#x000a0; &#x000a0;of some colon polyps.&#x000a0;</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 267px; height: 26px; text-align: center;" rowspan="1" colspan="1">Retinoblastoma gene (<italic toggle="yes">RB</italic>)</td>
                <td style="width: 107.2px; height: 26px; text-align: center;" rowspan="1" colspan="1">Genetic marker</td>
                <td style="width: 191.8px; height: 26px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Tumor suppressor gene&#x000a0;</td>
                <td style="width: 198px; height: 26px; text-align: center;" rowspan="1" colspan="1">Directly or indirectly mutated in almost all human cancers.&#x000a0;<xref ref-type="bibr" rid="article-145903.r61">[61]</xref>&#x000a0;&#x000a0;</td>
                <td style="width: 192px; height: 26px; text-align: center;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;-</td>
              </tr>
              <tr style="height: 52px;">
                <td style="width: 267px; height: 52px; text-align: center;" rowspan="1" colspan="1">&#x000a0;<italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic>&#x000a0;</td>
                <td style="width: 107.2px; height: 52px; text-align: center;" rowspan="1" colspan="1">Genetic marker</td>
                <td style="width: 191.8px; height: 52px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Tumor suppressor gene&#x000a0;</td>
                <td style="width: 198px; height: 52px; text-align: center;" rowspan="1" colspan="1">Mutation predisposes to many cancers in both sexes.<xref ref-type="bibr" rid="article-145903.r3">[3]</xref></td>
                <td style="width: 192px; height: 52px; text-align: center;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;-&#x000a0;</td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 267px; height: 39px; text-align: center;" rowspan="1" colspan="1">Adenomatous polyposis coli gene (<italic toggle="yes">APC</italic>)</td>
                <td style="width: 107.2px; height: 39px; text-align: center;" rowspan="1" colspan="1">Genetic marker</td>
                <td style="width: 191.8px; height: 39px; text-align: center;" rowspan="1" colspan="1">&#x000a0;Tumor suppressor gene</td>
                <td style="width: 198px; height: 39px; text-align: center;" rowspan="1" colspan="1">Hereditary nonpolyposis colonic, breast, and esophageal adenocarcinomas.<xref ref-type="bibr" rid="article-145903.r50">[50]</xref></td>
                <td style="width: 192px; height: 39px; text-align: center;" rowspan="1" colspan="1">Will be elevated in the presence&#x000a0; of some colon polyps.</td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 267px; height: 39px; text-align: center;" rowspan="1" colspan="1">&#x000a0;<italic toggle="yes">ras</italic></td>
                <td style="width: 107.2px; height: 39px; text-align: center;" rowspan="1" colspan="1">Genetic marker</td>
                <td style="width: 191.8px; height: 39px; text-align: center;" rowspan="1" colspan="1">Proto-oncogene</td>
                <td style="width: 198px; height: 39px; text-align: center;" rowspan="1" colspan="1">Mutations in <italic toggle="yes">ras</italic> are found in most human cancers.<xref ref-type="bibr" rid="article-145903.r62">[62]</xref></td>
                <td style="width: 192px; height: 39px; text-align: center;" rowspan="1" colspan="1">Mutations are almost ubiquitous and complex.</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 267px; height: 26px; text-align: center;" rowspan="1" colspan="1">&#x000a0;C-<italic toggle="yes">myc</italic></td>
                <td style="width: 107.2px; height: 26px; text-align: center;" rowspan="1" colspan="1">Genetic marker</td>
                <td style="width: 191.8px; height: 26px; text-align: center;" rowspan="1" colspan="1">Proto-oncogene</td>
                <td style="width: 198px; height: 26px; text-align: center;" rowspan="1" colspan="1">T-cell and B-cell lymphomas, small cell lung cancer. Used to identify a high-risk population.<xref ref-type="bibr" rid="article-145903.r63">[63]</xref></td>
                <td style="width: 192px; height: 26px; text-align: center;" rowspan="1" colspan="1">Varying expression is seen in different tumor types.</td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 267px; height: 39px; text-align: center;" rowspan="1" colspan="1">&#x000a0;<italic toggle="yes">b</italic><italic toggle="yes">cl-</italic>2</td>
                <td style="width: 107.2px; height: 39px; text-align: center;" rowspan="1" colspan="1">Genetic marker&#x000a0;</td>
                <td style="width: 191.8px; height: 39px; text-align: center;" rowspan="1" colspan="1">Oncogene promoting cell survival</td>
                <td style="width: 198px; height: 39px; text-align: center;" rowspan="1" colspan="1">Found in leukemia and lymphoma. Presence indicates resistance to chemotherapy.<xref ref-type="bibr" rid="article-145903.r64">[64]</xref>&#x000a0;</td>
                <td style="width: 192px; height: 39px; text-align: center;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;-&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-145903.s9" sec-type="Quality Control and Lab Safety&#x0000d;&#x0000a;">
        <title>Quality Control and Lab Safety
</title>
        <p>The testing laboratory is responsible for implementing stringent quality control measures to ensure the accuracy and reliability of the test. Assays should be validated before clinical use to ensure the provision of accurate and relevant reports. Recommended intra-assay and interassay variability are &#x0003c;5% and &#x0003c;10%, respectively.&#x000a0;Some newer techniques may perform significantly better&#x000a0;but may be less precise.<xref ref-type="bibr" rid="article-145903.r12">[12]</xref></p>
        <p>Aspects of quality control, such as internal and proficiency testing (PT), should be implemented. The quality control specimen should mimic sera, and multiple levels can be used to cover the range of concentration, including the decision limits. It is important to include negative and low-positive controls.<xref ref-type="bibr" rid="article-145903.r65">[65]</xref> The number of internal quality control samples to be run for marker assay validation depends on the frequency of testing. The samples should be checked frequently for assay interferences.&#x000a0;During tumor marker assay, calibration and daily maintenance should be conducted before running quality control (QC) samples.<xref ref-type="bibr" rid="article-145903.r66">[66]</xref>&#x000a0;</p>
        <p>Immediate and appropriate action should be taken to avoid erroneous reporting when an assay run fails to meet objective criteria for assay acceptance. Criteria for acceptance should be predefined and based on logical criteria such as those of Westgard.&#x000a0;The number of IQC specimens included per run should allow the identification of an unacceptable run with a given probability appropriate to the clinical application.<xref ref-type="bibr" rid="article-145903.r67">[67]</xref>&#x000a0;Given the long-term monitoring of cancer care, assay stability should be ensured over prolonged periods. Laboratories should have procedures and acceptance criteria for assessing lot-to-lot variation&#x000a0;that may adversely affect clinical outcomes.<xref ref-type="bibr" rid="article-145903.r68">[68]</xref></p>
        <p>Quality control (QC) material not provided by the method manufacturer is preferable; kit controls may provide an overly optimistic impression of performance as they are unlikely to be commutable with patient serum. At least one authentic serum matrix control from an independent source should be included in addition to any QC materials provided by the method manufacturer.<xref ref-type="bibr" rid="article-145903.r66">[66]</xref></p>
        <p>PT specimens should be commutable with patient specimens to ensure valid between-method comparisons.<xref ref-type="bibr" rid="article-145903.r69">[69]</xref>&#x000a0;Concentrations should assess performance over the working range and should include an assessment of linearity on dilution, baseline security, and stability of results over time. The PT provider is responsible for ensuring that specimens are stable in transit. The target values, usually consensus means for heterogeneous analytes,&#x000a0;should be accurate and stable, as demonstrated by assessing their accuracy, stability, and linearity on dilution.<xref ref-type="bibr" rid="article-145903.r70">[70]</xref></p>
        <p>When performing tumor biomarker assays, adhere to standard laboratory safety practices, including personal protective equipment, handling and disposal of biohazardous materials properly, and maintaining a clean work environment. Follow equipment maintenance and calibration protocols, and ensure staff is trained in emergency procedures to promote a safe and efficient laboratory environment.<xref ref-type="bibr" rid="article-145903.r71">[71]</xref></p>
      </sec>
      <sec id="article-145903.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Tumor biomarker assay requires a multifaceted approach. Laboratory technicians with expertise in running tumor marker assays are essential to ensure accurate testing. Lab professionals' roles include selecting appropriate assays for specific cancer types, establishing appropriate cutoff values, and determining the significance of marker trends over time. Clinicians should have a strategy toward&#x000a0;evidence-based practices and the clinical utility of tumor marker assays.</p>
        <p>Healthcare providers should uphold ethical principles while discussing test results, potential limitations, and implications for treatment choices. Patient safety is of paramount importance throughout the assay process. Adequate measures should be in place to prevent contamination, ensure specimen integrity, and safeguard patient information. Interprofessional communication and coordination are crucial for seamless care. Collaboration among physicians, pathologists, laboratory technicians, and other healthcare professionals ensures accurate sample collection, timely test results, and effective integration of tumor marker data into patient management plans.&#x000a0;This collaborative effort enhances care coordination within a concise framework.</p>
      </sec>
      <sec id="article-145903.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=145903&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=145903">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/145903/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=145903">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-145903.s12">
        <title>References</title>
        <ref id="article-145903.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tumor markers in clinical practice: General principles and guidelines.</article-title>
            <source>Indian J Med Paediatr Oncol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">20668599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagpal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chauhan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zaidi</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Tumor markers: A diagnostic tool.</article-title>
            <source>Natl J Maxillofac Surg</source>
            <year>2016</year>
            <season>Jan-Jun</season>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-20</page-range>
            <pub-id pub-id-type="pmid">28163473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malati</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Tumour markers: An overview.</article-title>
            <source>Indian J Clin Biochem</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>17</fpage>
            <page-range>17-31</page-range>
            <pub-id pub-id-type="pmid">23105677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhatt</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Mathur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Farooque</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dwarakanath</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Cancer biomarkers - current perspectives.</article-title>
            <source>Indian J Med Res</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>132</volume>
            <fpage>129</fpage>
            <page-range>129-49</page-range>
            <pub-id pub-id-type="pmid">20716813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zygulska</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Pierzchalski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Novel Diagnostic Biomarkers in Colorectal Cancer.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Jan</month>
            <day>13</day>
            <volume>23</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">35055034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Upadhyay</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer: An unknown territory; rethinking before going ahead.</article-title>
            <source>Genes Dis</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>655</fpage>
            <page-range>655-661</page-range>
            <pub-id pub-id-type="pmid">34291136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamilton</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>How are multifactorial beliefs about the role of genetics and behavior in cancer causation associated with cancer risk cognitions and emotions in the US population?</article-title>
            <source>Psychooncology</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>640</fpage>
            <page-range>640-647</page-range>
            <pub-id pub-id-type="pmid">29024169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mbemi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Njiki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yedjou</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Tchounwou</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Impact of Gene-Environment Interactions on Cancer Development.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2020</year>
            <month>Nov</month>
            <day>03</day>
            <volume>17</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">33153024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sung</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ferlay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Laversanne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soerjomataram</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2021</year>
            <month>May</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-249</page-range>
            <pub-id pub-id-type="pmid">33538338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Holman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Boehm</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Peipins</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Henley</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Age and cancer risk: a potentially modifiable relationship.</article-title>
            <source>Am J Prev Med</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>3 Suppl 1</issue>
            <fpage>S7</fpage>
            <page-range>S7-15</page-range>
            <pub-id pub-id-type="pmid">24512933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sewpersad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pillay</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Historical perspectives in clinical pathology: Bence Jones protein-early urine chemistry and the impact on modern day diagnostics.</article-title>
            <source>J Clin Pathol</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>212</fpage>
            <page-range>212-215</page-range>
            <pub-id pub-id-type="pmid">32471887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sturgeon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Duffy</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Stenman</surname>
                <given-names>UH</given-names>
              </name>
              <name>
                <surname>Lilja</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;nner</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Babaian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bast</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Dowell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Esteva</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Haglund</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Harbeck</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Holten-Andersen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klee</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Lamerz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Looijenga</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Rittenhouse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Semjonow</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>IeM</given-names>
              </name>
              <name>
                <surname>Sibley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>S&#x000f6;l&#x000e9;tormos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stephan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sokoll</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Diamandis</surname>
                <given-names>EP</given-names>
              </name>
              <collab>National Academy of Clinical Biochemistry</collab>
            </person-group>
            <article-title>National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.</article-title>
            <source>Clin Chem</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>12</issue>
            <fpage>e11</fpage>
            <page-range>e11-79</page-range>
            <pub-id pub-id-type="pmid">19042984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duffy</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical uses of tumor markers: a critical review.</article-title>
            <source>Crit Rev Clin Lab Sci</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>225</fpage>
            <page-range>225-62</page-range>
            <pub-id pub-id-type="pmid">11451209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quintanilla-Martinez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tinguely</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bonzheim</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fend</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>[Bone marrow biopsy: processing and use of molecular techniques].</article-title>
            <source>Pathologe</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>481</fpage>
            <page-range>481-9</page-range>
            <pub-id pub-id-type="pmid">23085692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vartanian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Slottke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johnstone</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Casale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Planck</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Gene expression profiling of whole blood: comparison of target preparation methods for accurate and reproducible microarray analysis.</article-title>
            <source>BMC Genomics</source>
            <year>2009</year>
            <month>Jan</month>
            <day>05</day>
            <volume>10</volume>
            <fpage>2</fpage>
            <pub-id pub-id-type="pmid">19123946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hojat</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>An Introduction to the Performance of Immunohistochemistry.</article-title>
            <source>Methods Mol Biol</source>
            <year>2019</year>
            <volume>1897</volume>
            <fpage>289</fpage>
            <page-range>289-298</page-range>
            <pub-id pub-id-type="pmid">30539453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases.</article-title>
            <source>Sci Rep</source>
            <year>2020</year>
            <month>Jun</month>
            <day>01</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>8820</fpage>
            <pub-id pub-id-type="pmid">32483216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Kwast</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santonja</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pihl</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Neetens</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Martikainen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Di Lollo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bubendorf</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hoedemaeker</surname>
                <given-names>RF</given-names>
              </name>
              <collab>Members of the pathology committee of the European Randomised Study of Screening for Prostate Cancer</collab>
            </person-group>
            <article-title>Guidelines for processing and reporting of prostatic needle biopsies.</article-title>
            <source>J Clin Pathol</source>
            <year>2003</year>
            <month>May</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>336</fpage>
            <page-range>336-40</page-range>
            <pub-id pub-id-type="pmid">12719451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sturgeon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Ch'ng</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hammond</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Liotta</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Petricoin</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Semmes</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>S&#x000f6;letormos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van der Merwe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Diamandis</surname>
                <given-names>EP</given-names>
              </name>
              <collab>National Academy of Clinical Biochemistry</collab>
            </person-group>
            <article-title>National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements.</article-title>
            <source>Clin Chem</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>54</volume>
            <issue>8</issue>
            <fpage>e1</fpage>
            <page-range>e1-e10</page-range>
            <pub-id pub-id-type="pmid">18606634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mosley</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Heat treatment of human serum to inactivate HIV does not alter protein binding of selected drugs.</article-title>
            <source>Ther Drug Monit</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>477</fpage>
            <page-range>477-9</page-range>
            <pub-id pub-id-type="pmid">9263392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Colorimetric immunoassay for detection of tumor markers.</article-title>
            <source>Int J Mol Sci</source>
            <year>2010</year>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>5077</fpage>
            <page-range>5077-94</page-range>
            <pub-id pub-id-type="pmid">21614193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hjemdahl</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Catecholamine measurements by high-performance liquid chromatography.</article-title>
            <source>Am J Physiol</source>
            <year>1984</year>
            <month>Jul</month>
            <volume>247</volume>
            <issue>1 Pt 1</issue>
            <fpage>E13</fpage>
            <page-range>E13-20</page-range>
            <pub-id pub-id-type="pmid">6377918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaha</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Significance of immunohistochemistry in breast cancer.</article-title>
            <source>World J Clin Oncol</source>
            <year>2014</year>
            <month>Aug</month>
            <day>10</day>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>382</fpage>
            <page-range>382-92</page-range>
            <pub-id pub-id-type="pmid">25114853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ishida</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zubair</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <chapter-title>Molecular Genetics Testing</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">32809547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Signoroni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vitellaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sala</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bertario</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers in familial adenomatous polyposis: role and significance.</article-title>
            <source>Front Biosci (Schol Ed)</source>
            <year>2010</year>
            <month>Jan</month>
            <day>01</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>413</fpage>
            <page-range>413-21</page-range>
            <pub-id pub-id-type="pmid">20036957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raj</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Gomella</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>Utilization of polymerase chain reaction technology in the detection of solid tumors.</article-title>
            <source>Cancer</source>
            <year>1998</year>
            <month>Apr</month>
            <day>15</day>
            <volume>82</volume>
            <issue>8</issue>
            <fpage>1419</fpage>
            <page-range>1419-42</page-range>
            <pub-id pub-id-type="pmid">9554517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Virtanen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Woodgett</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical uses of microarrays in cancer research.</article-title>
            <source>Methods Mol Med</source>
            <year>2008</year>
            <volume>141</volume>
            <fpage>87</fpage>
            <page-range>87-113</page-range>
            <pub-id pub-id-type="pmid">18453086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrawal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Greytak</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.</article-title>
            <source>Semin Cancer Biol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>Pt 2</issue>
            <fpage>26</fpage>
            <page-range>26-38</page-range>
            <pub-id pub-id-type="pmid">29258857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ankerst</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification.</article-title>
            <source>Arch Ital Urol Androl</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>125</fpage>
            <page-range>125-9</page-range>
            <pub-id pub-id-type="pmid">17269614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Co&#x0015f;kun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aarsand</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Sandberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guerra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-Garz&#x000f3;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fernandez-Calle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ceriotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jonker</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Carobene</surname>
                <given-names>A</given-names>
              </name>
              <collab>European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation</collab>
            </person-group>
            <article-title>Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2022</year>
            <month>Mar</month>
            <day>28</day>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>543</fpage>
            <page-range>543-552</page-range>
            <pub-id pub-id-type="pmid">33964202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sturgeon</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Standardization of tumor markers - priorities identified through external quality assessment.</article-title>
            <source>Scand J Clin Lab Invest Suppl</source>
            <year>2016</year>
            <volume>245</volume>
            <fpage>S94</fpage>
            <page-range>S94-9</page-range>
            <pub-id pub-id-type="pmid">27542005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jassam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Briscoe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Horner</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>The hook effect: a need for constant vigilance.</article-title>
            <source>Ann Clin Biochem</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>Pt 4</issue>
            <fpage>314</fpage>
            <page-range>314-7</page-range>
            <pub-id pub-id-type="pmid">16824284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reinsberg</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Interference by human antibodies with tumor marker assays.</article-title>
            <source>Hybridoma</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>205</fpage>
            <page-range>205-8</page-range>
            <pub-id pub-id-type="pmid">7590781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bolstad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Nustad</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Heterophilic antibody interference in immunometric assays.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>647</fpage>
            <page-range>647-61</page-range>
            <pub-id pub-id-type="pmid">24094636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banfi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salvagno</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Lippi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2007</year>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>565</fpage>
            <page-range>565-76</page-range>
            <pub-id pub-id-type="pmid">17484616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horn</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Pesce</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Reference intervals: an update.</article-title>
            <source>Clin Chim Acta</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>334</volume>
            <issue>1-2</issue>
            <fpage>5</fpage>
            <page-range>5-23</page-range>
            <pub-id pub-id-type="pmid">12867273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayes</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Biomarker validation and testing.</article-title>
            <source>Mol Oncol</source>
            <year>2015</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>960</fpage>
            <page-range>960-6</page-range>
            <pub-id pub-id-type="pmid">25458054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duffy</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Tumor markers in clinical practice: a review focusing on common solid cancers.</article-title>
            <source>Med Princ Pract</source>
            <year>2013</year>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-11</page-range>
            <pub-id pub-id-type="pmid">22584792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marques-Garcia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boned</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Lao</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Braga</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carobene</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coskun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-Garz&#x000f3;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Calle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Perich</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jonker</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aslan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Sandberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aarsand</surname>
                <given-names>AK</given-names>
              </name>
              <collab>European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation and Task Group for the Biological Variation Database</collab>
            </person-group>
            <article-title>Critical review and meta-analysis of biological variation estimates for tumor markers.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2022</year>
            <month>Mar</month>
            <day>28</day>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>494</fpage>
            <page-range>494-504</page-range>
            <pub-id pub-id-type="pmid">35143717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arlen</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Bianco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dahut</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Figg</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Freedland</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Gulley</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kantoff</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Kattan</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Regan</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Sartor</surname>
                <given-names>O</given-names>
              </name>
              <collab>Prostate Specific Antigen Working Group</collab>
            </person-group>
            <article-title>Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.</article-title>
            <source>J Urol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>179</volume>
            <issue>6</issue>
            <fpage>2181</fpage>
            <page-range>2181-5; discussion 2185-6</page-range>
            <pub-id pub-id-type="pmid">18423743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coppolino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bolignano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rivoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mazza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Presta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fuiano</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Tumour markers and kidney function: a systematic review.</article-title>
            <source>Biomed Res Int</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>647541</fpage>
            <pub-id pub-id-type="pmid">24689048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maestranzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Przemioslo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sherwood</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA.</article-title>
            <source>Ann Clin Biochem</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>35 ( Pt 1)</volume>
            <fpage>99</fpage>
            <page-range>99-103</page-range>
            <pub-id pub-id-type="pmid">9463746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Taee</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Al-Safar</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Al-Falahi</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Al-Shamma</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>The Clinical Significance of beta2-microglobulin in End-Stage Renal Disease.</article-title>
            <source>Saudi J Kidney Dis Transpl</source>
            <year>2003</year>
            <season>Oct-Dec</season>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>492</fpage>
            <page-range>492-6</page-range>
            <pub-id pub-id-type="pmid">17657122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gish</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.</article-title>
            <source>Clin Liver Dis</source>
            <year>2015</year>
            <month>May</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>309</fpage>
            <page-range>309-23</page-range>
            <pub-id pub-id-type="pmid">25921665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammarstr&#x000f6;m</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.</article-title>
            <source>Semin Cancer Biol</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>67</fpage>
            <page-range>67-81</page-range>
            <pub-id pub-id-type="pmid">10202129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narayanan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Alkaline phosphatase as tumor marker.</article-title>
            <source>Ann Clin Lab Sci</source>
            <year>1983</year>
            <season>Mar-Apr</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-6</page-range>
            <pub-id pub-id-type="pmid">6859804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>WI</given-names>
              </name>
            </person-group>
            <article-title>Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma.</article-title>
            <source>Cancer Med</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>1311</fpage>
            <page-range>1311-1322</page-range>
            <pub-id pub-id-type="pmid">28493412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jurisic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Radenkovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Konjevic</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2015</year>
            <volume>867</volume>
            <fpage>115</fpage>
            <page-range>115-24</page-range>
            <pub-id pub-id-type="pmid">26530363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kong</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Emerging roles of human prostatic Acid phosphatase.</article-title>
            <source>Biomol Ther (Seoul)</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-20</page-range>
            <pub-id pub-id-type="pmid">24009853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beketic-Oreskovic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maric</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ozretic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oreskovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ajdukovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levanat</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Assessing the clinical significance of tumor markers in common neoplasms.</article-title>
            <source>Front Biosci (Elite Ed)</source>
            <year>2012</year>
            <month>Jun</month>
            <day>01</day>
            <volume>4</volume>
            <issue>7</issue>
            <fpage>2558</fpage>
            <page-range>2558-78</page-range>
            <pub-id pub-id-type="pmid">22652661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boime</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ben-Menahem</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Glycoprotein hormone structure-function and analog design.</article-title>
            <source>Recent Prog Horm Res</source>
            <year>1999</year>
            <volume>54</volume>
            <fpage>271</fpage>
            <page-range>271-88; discussion 288-9</page-range>
            <pub-id pub-id-type="pmid">10548880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Majumdar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mangal</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>Hyperprolactinemia.</article-title>
            <source>J Hum Reprod Sci</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>168</fpage>
            <page-range>168-75</page-range>
            <pub-id pub-id-type="pmid">24347930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiriakopoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giannakis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Menenakos</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Calcitonin: current concepts and differential diagnosis.</article-title>
            <source>Ther Adv Endocrinol Metab</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>20420188221099344</fpage>
            <pub-id pub-id-type="pmid">35614985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neumann</surname>
                <given-names>HPH</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pheochromocytoma and Paraganglioma.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Aug</month>
            <day>08</day>
            <volume>381</volume>
            <issue>6</issue>
            <fpage>552</fpage>
            <page-range>552-565</page-range>
            <pub-id pub-id-type="pmid">31390501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maroun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kocha</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kvols</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bjarnason</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Germond</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poitras</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rayson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sideris</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.</article-title>
            <source>Curr Oncol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>67</fpage>
            <page-range>67-76</page-range>
            <pub-id pub-id-type="pmid">17576444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asif</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Teply</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers for Treatment Response in Advanced Prostate Cancer.</article-title>
            <source>Cancers (Basel)</source>
            <year>2021</year>
            <month>Nov</month>
            <day>16</day>
            <volume>13</volume>
            <issue>22</issue>
            <pub-id pub-id-type="pmid">34830878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Current status of active surveillance in prostate cancer.</article-title>
            <source>Investig Clin Urol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-20</page-range>
            <pub-id pub-id-type="pmid">26966722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rein</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dada</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Safi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Michener</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Potential markers for detection and monitoring of ovarian cancer.</article-title>
            <source>J Oncol</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>475983</fpage>
            <pub-id pub-id-type="pmid">21577260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prpi&#x00107;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franceschi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Romi&#x00107;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Juki&#x00107;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kusi&#x00107;</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>THYROGLOBULIN AS A TUMOR MARKER IN DIFFERENTIATED THYROID CANCER - CLINICAL CONSIDERATIONS.</article-title>
            <source>Acta Clin Croat</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>518</fpage>
            <page-range>518-527</page-range>
            <pub-id pub-id-type="pmid">31168186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Onitilo</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Greenlee</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Mukesh</surname>
                <given-names>BN</given-names>
              </name>
            </person-group>
            <article-title>Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.</article-title>
            <source>Clin Med Res</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>1-2</issue>
            <fpage>4</fpage>
            <page-range>4-13</page-range>
            <pub-id pub-id-type="pmid">19574486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dimaras</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Corson</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Cobrinik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Munier</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Abramson</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Chantada</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Njuguna</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gallie</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Retinoblastoma.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2015</year>
            <month>Aug</month>
            <day>27</day>
            <volume>1</volume>
            <fpage>15021</fpage>
            <pub-id pub-id-type="pmid">27189421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fern&#x000e1;ndez-Medarde</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Ras in cancer and developmental diseases.</article-title>
            <source>Genes Cancer</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>344</fpage>
            <page-range>344-58</page-range>
            <pub-id pub-id-type="pmid">21779504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Papenhausen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects.</article-title>
            <source>Genes (Basel)</source>
            <year>2017</year>
            <month>Apr</month>
            <day>05</day>
            <volume>8</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">28379189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Dash</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Emdad</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Dent</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Pellecchia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarkar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Targeting the Bcl-2 family for cancer therapy.</article-title>
            <source>Expert Opin Ther Targets</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-75</page-range>
            <pub-id pub-id-type="pmid">23173842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badrick</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Quality leadership and quality control.</article-title>
            <source>Clin Biochem Rev</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>81</fpage>
            <page-range>81-93</page-range>
            <pub-id pub-id-type="pmid">18568046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kinns</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pitkin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Housley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Internal quality control: best practice.</article-title>
            <source>J Clin Pathol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>66</volume>
            <issue>12</issue>
            <fpage>1027</fpage>
            <page-range>1027-32</page-range>
            <pub-id pub-id-type="pmid">24072731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mrazek</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lippi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Keppel</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Felder</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Oberkofler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haschke-Becher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cadamuro</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Errors within the total laboratory testing process, from test selection to medical decision-making - A review of causes, consequences, surveillance and solutions.</article-title>
            <source>Biochem Med (Zagreb)</source>
            <year>2020</year>
            <month>Jun</month>
            <day>15</day>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>020502</fpage>
            <pub-id pub-id-type="pmid">32550813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdollahi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saffar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saffar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Types and Frequency of Errors during Different Phases of Testing At a Clinical Medical Laboratory of a Teaching Hospital in Tehran, Iran.</article-title>
            <source>N Am J Med Sci</source>
            <year>2014</year>
            <month>May</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>224</fpage>
            <page-range>224-8</page-range>
            <pub-id pub-id-type="pmid">24926448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vesper</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Reference materials and commutability.</article-title>
            <source>Clin Biochem Rev</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>139</fpage>
            <page-range>139-47</page-range>
            <pub-id pub-id-type="pmid">18392124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>The role of proficiency testing in achieving standardization and harmonization between laboratories.</article-title>
            <source>Clin Biochem</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>4-5</issue>
            <fpage>232</fpage>
            <page-range>232-5</page-range>
            <pub-id pub-id-type="pmid">19863911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145903.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ionescu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Negu&#x00163;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Combiescu</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>[Biosafety and biosecurity in the medical laboratory. Update and trends].</article-title>
            <source>Bacteriol Virusol Parazitol Epidemiol</source>
            <year>2007</year>
            <season>Jul-Dec</season>
            <volume>52</volume>
            <issue>3-4</issue>
            <fpage>91</fpage>
            <page-range>91-9</page-range>
            <pub-id pub-id-type="pmid">19326721</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
